Feature Image: 
Mobile Feature Image: 
Feature Title: 
Our purpose is simple:
Feature Body: 
To be a catalyst for amplifying the concerns of those speaking for patients about any proposals that deny or restrict access to potentially life-saving medicines.


An organization most patients never heard of is now hard at work determining whether recently approved drugs for serious and often life-threatening diseases should be covered by private health plans and made available to patients.

Called the Institute for Clinical and Economic Review (ICER), this Boston-based institute describes itself as “a trustworthy, independent source to help assess how valuable a new drug really is.” Yet, ICER has come under increasing criticism due to the methods it uses to decide the “value” of new medicines, and its ultimate purpose of limiting the use of drugs patients and clinicians need. 

Flexible Content Title: 
Flexible Content Body: 
  • Measuring the Value of Prescription Drugs
  • Are Biopharmaceutical Budget Caps Good Public Policy?
  • Institutional Health Care Rationing Ignores Patients, Undermines Progress, and Leads to Deterioration of Care
  • Not at Any Price: How ICER Robs Myeloma Patients of Life and Hope

Read Research Papers

Patients Rising Comments to ICER on Psoriasis Draft Evidence Report | By: Terry Wilcox

Patients Rising is a Washington, DC-based non-profit organization with a very specific mission: we advocate for access to vital therapies and services for all patients with life-threatening and chronic diseases.  That is why Patients Rising is com

ICER (.@icer_review) on Thursday announced a Draft Evidence Report focused on the comparative clinical effectivenes… https://t.co/cYCZApAGzY

3 days ago t.co/ICERWATCH/..

RT @HeoroCom: #Model: #nivolumab is #costeffective vs #cetuximab (#ICER = $89,786/QALY) but not vs #methotrexate or #docetaxel in metastati…

4 days ago t.co/ICERWATCH/..